Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]
An article appearing today the Urology Times E-News rang a warning bell about the use of the angiogenesis inhibitor bevacizumab (Avastin). The article warned that men with advanced prostate cancer may be at an increased risk of treatment-related death when bevacizumab is used in combination with other therapies. Senior author Shenhong Wu, MD, PhD, and [...]
A member of the advanced prostate cancer on-line group recently posted about his experience using the newly approved chemotherapy agent, Jevtana (cabazitaxel). His post included not only a report about his PSA response to the drug, but his experiences with side effects and a suggested method of controlling one of the debilitating side effect, diarrhea. [...]
Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against [...]
In order to get FDA approval, drugs must first go through a clinical trial that demonstrates that they offer a better treatment result than the current standard of care. In some instances the better result can be a demonstration that the investigational drug provides an advantage which is only palliative (as Mitoxantrone does for advance [...]